It seems that every few months a new biomarker gets discussed that has potential to be impactful for screening or diagnosing patients with Alzheimer’s disease. Cerebrospinal fluid (CSF)-based beta-amyloid tests are now available on the market that correlate with positron emission tomography (PET) imaging, but where do the rest of these biomarkers for Alzheimer’s disease fit? Are pTau217, pTau181 and total Tau equally important and useful? Where do GFAP and NfL fit in this milieu?
This webinar will present a general survey of the current notable biomarkers for Alzheimer’s disease and where each may fit within the Alzheimer’s diagnostic landscape. The featured speaker will discuss the positives and challenges in testing for these individual markers and how these tests might be used in clinical trials now and in the clinic in the future.
Katherine T. Landschulz, PhD, Sr Director and Therapeutic Area Lead, Neurodegenerative Diseases, Labcorp Biomarker Solution Center
As Neurodegeneration Therapeutic Area Lead for the Labcorp Biomarker Solution Center, Dr. Landschulz is responsible for the delivery of biomarker strategies for sponsor programs in Alzheimer’s, Parkinson’s and other neurodegenerative disease indications. Dr. Landschulz serves as a consultant to sponsors and teams, advising regarding biomarker selection and strategy development, laboratory placement of testing, feasibility designs, and overall guidance around translational and exploratory biomarker data in drug development. Dr. Landschulz serves further as a liaison, directing questions and connecting sponsor and Labcorp biomarker scientists. Finally, Dr. Landschulz participates in enterprise-wide assessments, licensing and implementation of new laboratory biomarker and tests transitioning from clinical trial to clinical care utilization.Message Presenter
John W. Winslow, PhD. Director of Research and Development, Labcorp-Monogram Biosciences
Dr. Winslow is Director, R&D; Labcorp/Monogram Biosciences laboratory, and heads a group that is responsible for the innovation, development and validation of diagnostic assays supporting biomarker-guided, personalized neurology and oncology patient treatment. Dr. Winslow and group also actively develop and apply biomarker testing to support pharmaceutical/biotechnology company pre-clinical and clinical evaluation of novel therapeutics. Dr. Winslow is an enterprise-wide contributor to multiple R&D committees and project teams assessing emerging technologies for further evaluation, licensing and implementation, primarily in neurology and oncology. He is an active participant in several major scientific conferences and frequently presents results from collaborative biomarker assay development and translational studies. Dr. Winslow is a co-author of over 60 peer-reviewed scientific publications, and 20 issued patents.Message Presenter
Who Should Attend?
This webinar will appeal to:
- Researchers, scientists, clinicians, academicians and professionals from pharmaceutical companies, bio-pharma companies as well as universities and research institutes working in:
- Biomarker discovery/development
- Biomarkers for Neurological disorders
- Clinical Biomarkers
- Companion Diagnostics
- Personalized Medicine
- Tailored Therapeutics
- Translational Medicine and Science
What You Will Learn
Attendees will learn about the current information on important biomarkers for Alzheimer’s disease and the utility of each based on clinical evidence and how these markers impact current and future treatment options.
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. Learn more about Labcorp at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.